In the last few years' immunotherapy has become an important cancer treatment option. While the principles of immunotherapy evolved, only sipuleucel-T was approved by the Food and Drug Administration (FDA) which lead to further studies with other agents, starting a new era in immuno-oncology. A...
Prostate Cancer Treatment Overview This year in the United States, there will be over 230,000 new prostate cancer diagnoses, making prostate cancer the most common type of cancer affecting men. Chances are either you or someone you know will develop the disease. ...
According to Dr. Raman, "This image-guided therapy maximizes our ability to killcancer cellswhile minimizingcollateral damageto the prostate to achieve the ultimate trifecta inprostate cancer treatment: full local cancer control while maintaining urinary continence and potency. The latter are the complic...
Prostate cancer (PC) care is rapidly evolving, with improved treatment options and outcomes. Trials recently published in the New England Journal of Medicine report on an oral lutenizing-hormone-releasing hormone antagonist with superior endocrine and tolerability profiles and positive outcomes for non-...
The treatment plan for prostate cancer depends on the size, location, extent of the disease, and the patient’s physical condition. In St. Stamford Modern Cancer Hospital Guangzhou, experts from Multidisiplinary Team (MDT) will jointly hold a consultation and discuss appropriate treatment options ...
Prostate cancer is the most common form of cancer in men in Western countries. There are approximately 1.1 million new cases around the world per year, and approx. 310,000 die from prostate cancer (GLOBOCAN). There was over four times the incidence of prostate cancer in 2017 as in the 195...
Prostate cancer is a hormone-dependent malignancy, whose onset and progression are closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this critical role of AR signaling in driving prostate cancer, therapy targeting th
Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, diseas
By reducing the amount and activity of testosterone, the growth of advanced prostate cancer is slowed. Hormone (endocrine) therapy, known as androgen ablation or androgen suppression therapy, is the main treatment for advanced prostate cancer. It is the first line of treatment for metastatic ...
Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment str...